Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)‘s stock had its “buy” rating restated by Seaport Global Securities in a research report issued on Friday, October 6th, Marketbeat Ratings reports. They presently have a $136.00 price objective on the biopharmaceutical company’s stock. Seaport Global Securities’ price objective indicates a potential upside of 101.66% from the stock’s previous close.
Other equities analysts also recently issued research reports about the stock. Citigroup Inc. reaffirmed a “neutral” rating and set a $150.00 target price on shares of Intercept Pharmaceuticals in a research note on Tuesday, September 19th. BidaskClub raised shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Laidlaw reissued a “hold” rating and set a $119.00 price target (up previously from $115.00) on shares of Intercept Pharmaceuticals in a research report on Tuesday, August 1st. UBS AG downgraded shares of Intercept Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Friday, September 22nd. Finally, Jefferies Group LLC reissued a “buy” rating and set a $275.00 price target on shares of Intercept Pharmaceuticals in a research report on Sunday, July 30th. Four investment analysts have rated the stock with a sell rating, ten have given a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $153.76.
Shares of Intercept Pharmaceuticals (ICPT) traded up 2.87% on Friday, reaching $67.37. The company had a trading volume of 965,434 shares. Intercept Pharmaceuticals has a 12 month low of $54.98 and a 12 month high of $147.52. The stock’s market cap is $1.69 billion. The stock has a 50-day moving average price of $85.96 and a 200-day moving average price of $108.58.
Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Monday, July 31st. The biopharmaceutical company reported ($3.46) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($3.62) by $0.16. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 135.24%. The business had revenue of $30.89 million during the quarter, compared to analyst estimates of $27.50 million. During the same period last year, the business posted ($3.14) earnings per share. Intercept Pharmaceuticals’s quarterly revenue was up 459.6% compared to the same quarter last year. Analysts predict that Intercept Pharmaceuticals will post ($13.99) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Intercept Pharmaceuticals, Inc. (ICPT) Rating Reiterated by Seaport Global Securities” was first posted by BBNS and is the sole property of of BBNS. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://baseballnewssource.com/markets/intercept-pharmaceuticals-inc-icpt-coverage-initiated-by-analysts-at-seaport-global-securities/1696739.html.
In other news, CEO Mark Pruzanski sold 1,532 shares of the business’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $58.87, for a total value of $90,188.84. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Daniel G. Welch sold 217 shares of the business’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $126.76, for a total transaction of $27,506.92. Following the completion of the sale, the director now owns 3,710 shares in the company, valued at $470,279.60. The disclosure for this sale can be found here. Over the last quarter, insiders sold 6,278 shares of company stock worth $592,796. 4.50% of the stock is currently owned by insiders.
Institutional investors have recently bought and sold shares of the company. Sphera Funds Management LTD. increased its holdings in shares of Intercept Pharmaceuticals by 100.0% in the 2nd quarter. Sphera Funds Management LTD. now owns 30,000 shares of the biopharmaceutical company’s stock worth $3,632,000 after buying an additional 15,000 shares during the last quarter. Oppenheimer & Co. Inc. grew its holdings in Intercept Pharmaceuticals by 9.0% during the 1st quarter. Oppenheimer & Co. Inc. now owns 2,152 shares of the biopharmaceutical company’s stock valued at $244,000 after purchasing an additional 178 shares during the last quarter. Geode Capital Management LLC grew its holdings in Intercept Pharmaceuticals by 12.8% during the 1st quarter. Geode Capital Management LLC now owns 144,130 shares of the biopharmaceutical company’s stock valued at $16,301,000 after purchasing an additional 16,392 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Intercept Pharmaceuticals by 10.2% during the 1st quarter. Bank of New York Mellon Corp now owns 68,302 shares of the biopharmaceutical company’s stock valued at $7,725,000 after purchasing an additional 6,312 shares during the last quarter. Finally, Asymmetry Capital Management L.P. bought a new position in Intercept Pharmaceuticals during the 2nd quarter valued at about $3,580,000. Hedge funds and other institutional investors own 82.19% of the company’s stock.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.